NovoEight 250IU Powder and Solvent for Solution for Injection

Manufacturer
Novo Nordisk A/S
 
Contents
Each powder vial contains nominally 250 IU human coagulation factor VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 62.5 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa.
 
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
 
Instruction
Intravenous use. NovoEight is to be administered intravenously after reconstitution of the powder with the solvent supplied in the syringe. After reconstitution the solution appears as a clear or slightly opalescent solution. Do not use solutions that are cloudy or have deposits.You will also need an infusion set (tubing and butterfly needle), sterile alcohol swabs, gauze pads and plasters. These devices are not included in the NovoEight package.Always use an aseptic technique.
 
Drug interaction
No interactions of human coagulation factor VIII (rDNA) products with other medicinal products have been reported.